International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
Image Credit:Int J Endocrinol Metab
Outline
Experience With 68 Girls With Turner’s Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone
Authors
Abstract
Short stature is a common feature in Turner’s syndrome; (TS) final height in untreated patients is on average 20cm below the population mean for adult women. When recombinant growth hormone (GH) became available, supraphysiologic GH doses with or without oxandrolone (OX) were administrated in order to improve growth in patients wih TS in several studies Objective: The objective of this study was to find out whether moderate doses of growth hormone in combination with oxandrolone and late initiation of puberty could improve adult height even in TS patients with late diagnosis. Materials and Methods: In this study the data an 68 patients with TS will be reported. Thirtythree patients with chronological age 17 years or above did not receive treatment. Thirty- five patients with TS were randomly assigned to receive either GH alone (0.375 mg/kg/week) by daily S.C injections (Group GH, n = 23) or in combination with OX 6 mg/kg/day P.O (group GH + OX, n = 12). Mean age at the onset of treatment was 10.7 years (GH) and 10.3 years (GH+OX), mean projected adult height (PAH) was 142.1 cm (GH) and 141.5 cm (GH+ ox). Puberty was induced at a mean age of 14.5 years. Results: There was a marked difference in group GH ± OX cumulative growth during 4.3 years of therapy in comparison with untreated TS patients. Twenty-six patients are now near or at final height: Group GH (n=17), mean final height was 148.7 cm (PAH 142.1 cm, gain 6.6 cm); group GH+ OX (n = 9), 151.9 cm (PAH, 141.5 cm, gain 9.4 cm). In the untreated group (n = 33), mean final height was 139.1 cm. Cumulative growth was more significant in GH plus OX than GH alone treated subjects (P<0.001). Conclusion: The diagnosis of TS is often delayed in our country and this defers the timely and appropriate treatment of short stature. Our results are in keeping with studies demonstrating moderate doses of GH plus OX and late induction of puberty are able to improve final height even in patients with TS, treated relatively late.
Highlights
References
- 1.The references are available in the PDF file.
Copyright
© 2005, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Body Mass Index in Turner Syndrome Before and After Growth Hormone Therapy
R V. Body Mass Index in Turner Syndrome Before and After Growth Hormone Therapy. Int J Endocrinol Metab. 2004;2(2):. doi:
Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty
Karamizadeh Z, Amirhakimi A, Amirhakimi G. Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly Progressive Puberty. Inn J Pediatr. 2014;24(3):. doi:
Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty
Giri D, Patil P, Blair J, Dharmaraj P, Ramakrishnan R, et al. Testosterone Therapy Improves the First Year Height Velocity in Adolescent Boys with Constitutional Delay of Growth and Puberty. Int J Endocrinol Metab. 2017;15(2):e42311. doi: https://doi.org/10.5812/ijem.42311
Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study
Apperley LJ, Ramakrishnan R, Dharmaraj P, Das U, Didi M, et al. Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study. Int J Endocrinol Metab. 2020;18(4):e107292. doi: https://doi.org/10.5812/ijem.107292
Current State of Growth Hormone Therapy
Mohammadian S, Sadeghi-Nejad A. Current State of Growth Hormone Therapy. Int J Endocrinol Metab. 2003;1(2):e94490. doi:
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 6 hours ago
- OpenAlex: 0
Last Update: 9 hours ago
- OpenCitations: 0
Last Update: 4 days ago